https://doi.org/10.4081/aiua.2025.13877
Efficacy of Serenoa repens lipido-sterolic extract alone or in combination with propolis polyphenols and Boswellia serrata extract suppositories on PSA level and symptoms in patients affected by lower urinary tract disorders
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 30 September 2025
Background: Standard medical treatments for patients with uncomplicated LUTS include alpha-blockers, 5-alpha-reductase inhibitors (5ARIs), phosphodiesterase type 5 inhibitors, antimuscarinics, and beta-3 agonists. The lipido-sterolic extract of Serenoa repens (Sr) is also recommended as a therapeutic option. Our study prospectively evaluated the impact of a 6-month assumption of lipido-sterolic extract of Sr alone or in combination with Phenolmicin P3 and Bosexil medical devices suppositories on symptoms and on PSA levels in patients affected by BPO related-LUTS.
Methods: We prospectively enrolled 509 patients: 194 (group 1) were prescribed only a 6-month assumption of Sr extract, while 315 (group 2) were also prescribed a 20-day therapy with Phenolmicin P3 and Bosexil medical devices suppositories.
Results: After 6 months, 371 patients’ data were registered and analyzed. Furthermore, patients’ withdrawal and motivations were also considered.
Conclusions: In our clinical study, the patients treated with Sr extract (320 mg daily) showed a significant relief regarding LUTS, and the association of a 6-month assumption of Sr extract with a 20-day prescription of Phenolmicin P3 and Bosexil medical device in suppository form seems to significantly improve both efficacy on LUTS and decrease of PSA levels.
Downloads
1. Gravas S, Cornu JN, Gacci M, et al. EAU guidelines on management of non-neurogenic male LUTS including benign prostatic obstruction. Arnhem, European Association of Urology. 2022.
2. Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)—Focus on the UK. Br J Urol 2014; 115:508-19.
3. Launer BM, McVary KT, Ricke WA, Lloyd GL. The rising worldwide impact of benign prostatic hyperplasia. Br J Urol 2020;127:722-8.
4. Serati M, Andersson KE, Dmochowski R, et al. Systematic review of combination drug therapy for non-neurogenic lower urinary tract Symptoms. Eur Urol 2019;75:129-68.
5. Gacci M, Ficarra V, Sebastianelli A, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med 2014; 11:1554-66.
6. Debruyne F, Koch G, Boyle P, et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: A 1-year randomized international study. Eur Urol 2002; 41:497-06.
7. Novara G, Giannarini G, Alcaraz A, et al. Efficacy and safety of hexanic lipidosterolic extract of Serenoa repens (permixon) in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. Eur Urol Focus 2016; 2:553-61.
8. Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1098 patients. Prostate 1996; 29:231-40.
9. Corona G, Tirabassi G, Santi D, et al. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: A comprehensive review and meta-analysis. Andrology 2017; 5:671-8.
10. De Nunzio C, Salonia A, Gacci M, Ficarra V. Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia. World J Urol 2020;38:2771-9.
11. Gandaglia G, Briganti A, Gontero P, et al. The role of chronic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 2013;112:432-41.
12. Goepel M, Hecker U, Krege S, et al. Saw palmetto extracts potently and noncompetitively inhibit human alpha1-adrenoceptors in vitro. Prostate 1999;38:208-15.
13. Oki T, Suzuki M, Nishioka Y, et al. Effects of saw palmetto extract on micturition reflex of rats and its autonomic receptor binding activity. J Urol 2005;173:1395-9.
14. Di Silverio F, Monti S, Sciarra A, et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 1998;37:77-83.
15. Andriole GL, McCullum-Hill C, Sandhu GS, et al. The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. J Urol 2013; 189:486-92.
16. Fagelman E, Lowe FC. Saw palmetto berry as a treatment for BPH. Rev Urol 2001; 3:134-8.
17. Kim SW. Phytotherapy: emerging therapeutic option in urologic disease. Transl Androl Urol 2012; 1:181-91.
18. Argirovic A, Argirovic D. Does the addition of Serenoa Repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia? Vojnosanit Pregl 2013; 70:1091-6.
19. Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2015;67:1099-109.
20. MacDonald R, Tacklind JW, Rutks I, et al. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU Int 2012;109:1756-61.
21. Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006;354:557-66.
22. Ooi SL, Pak SC. Serenoa repens for lower urinary tract symptoms/benign prostatic hyperplasia: current evidence and its clinical implications in naturopathic medicine. J Altern Complement Med. 2017; 23:599-606.
23. De Monte C, Carradori S, Granese A, et al. Modern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptoms. BMC Urol 2014; 14:63.
24. Agbabiaka TB, Pittler MH, Wider B, et al. Serenoa repens (saw palmetto): a systematic review of adverse events. Drug Saf 2009;32:637-47.
25. Poeckel D, Werz O. Boswellic acids: biological actions and molecular targets. Curr Med Chem 2006; 13:3359-69.
26. Siemoneit U, Koeberle A, Rossi A, et al. Inhibition of microsomal prostaglandin E2 synthase-1 as a molecular basis for the anti-inflammatory actions of boswellic acids from frankincense. Br J Pharmacol 2011;162:147-62.
27. Sibona M, Destefanis P, Agnello M, et al. The association of Boswellia resin extract and propolis derived polyphenols can improve quality of life in patients affected by prostatitis-like symptoms. Arch Ital Urol Androl 2020;91:251-5.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.